Edwards Lifesciences Co. (NYSE:EW) Holdings Trimmed by Wedmont Private Capital

Wedmont Private Capital lowered its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 8.7% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 7,950 shares of the medical research company’s stock after selling 754 shares during the period. Wedmont Private Capital’s holdings in Edwards Lifesciences were worth $513,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of EW. Clarity Capital Partners LLC acquired a new stake in shares of Edwards Lifesciences during the 4th quarter valued at $434,000. GLOBALT Investments LLC GA acquired a new stake in shares of Edwards Lifesciences during the 4th quarter valued at $945,000. V Square Quantitative Management LLC boosted its stake in shares of Edwards Lifesciences by 31.6% during the 4th quarter. V Square Quantitative Management LLC now owns 11,047 shares of the medical research company’s stock valued at $842,000 after buying an additional 2,652 shares during the period. Cim LLC acquired a new stake in shares of Edwards Lifesciences during the 4th quarter valued at $13,724,000. Finally, Tortoise Investment Management LLC boosted its stake in shares of Edwards Lifesciences by 140.2% during the 4th quarter. Tortoise Investment Management LLC now owns 1,441 shares of the medical research company’s stock valued at $110,000 after buying an additional 841 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on EW. Oppenheimer reissued an “outperform” rating and set a $90.00 target price on shares of Edwards Lifesciences in a research note on Thursday, September 12th. Citigroup reduced their price objective on shares of Edwards Lifesciences from $83.00 to $77.00 and set a “buy” rating for the company in a research note on Tuesday, October 1st. Baird R W lowered shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 25th. StockNews.com lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Thursday, July 25th. Finally, Jefferies Financial Group lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and reduced their price objective for the company from $85.00 to $70.00 in a research note on Wednesday, September 18th. Seventeen research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $75.77.

Insider Activity at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction dated Wednesday, September 11th. The shares were sold at an average price of $66.77, for a total value of $333,850.00. Following the sale, the vice president now owns 46,936 shares of the company’s stock, valued at $3,133,916.72. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction dated Wednesday, September 11th. The shares were sold at an average price of $66.77, for a total value of $333,850.00. Following the sale, the vice president now owns 46,936 shares of the company’s stock, valued at $3,133,916.72. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Daveen Chopra sold 1,250 shares of the company’s stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total transaction of $87,437.50. Following the completion of the sale, the vice president now directly owns 29,333 shares in the company, valued at approximately $2,051,843.35. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 11,250 shares of company stock valued at $751,688 over the last quarter. 1.29% of the stock is owned by company insiders.

Edwards Lifesciences Stock Performance

NYSE:EW opened at $68.13 on Friday. The firm’s 50-day moving average is $67.13 and its 200-day moving average is $80.17. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.87 and a current ratio of 3.71. The company has a market cap of $41.04 billion, a price-to-earnings ratio of 28.04, a PEG ratio of 2.83 and a beta of 1.13.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Wednesday, July 24th. The medical research company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.69 by $0.01. The company had revenue of $1.63 billion for the quarter, compared to the consensus estimate of $1.65 billion. Edwards Lifesciences had a net margin of 24.55% and a return on equity of 22.35%. The business’s revenue was up 6.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.66 EPS. Equities research analysts anticipate that Edwards Lifesciences Co. will post 2.71 earnings per share for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.